Schwannomatosis is a tumor suppressor syndrome that causes multiple tumors along peripheral nerves. Formal diagnostic criteria were first published in 2005. Variability in clinical presentation and a relative lack of awareness of the syndrome have contributed to difficulty recognizing affected individuals and accurately describing the natural history of the disorder. Many critical questions such as the mutations underlying schwannomatosis, genotype-phenotype correlations, inheritance patterns, pathologic diagnosis of schwannomatosisassociated schwannomas, tumor burden in schwannomatosis, the incidence of malignancy, and the effectiveness of current, or new treatments remain unanswered. A well-curated registry of schwannomatosis patients is needed to facilitate research in field. An international consortium of clinicians and scientists across multiple disciplines with expertise in schwannomatosis was established and charged with the task of designing and populating a schwannomatosis patient registry. The International Schwannomatosis Registry (ISR) was built around key data points that allow confirmation of the diagnosis and identification of potential research subjects to advance research to further the knowledge base for schwannomatosis. A registry with 389 participants enrolled to date has been established. Twenty-three additional subjects are pending review. A formal process has been established for scientific investigators to propose research projects, identify eligible subjects, and seek collaborators from ISR sites. Research collaborations have been created using the information collected by the registry and are currently being conducted. The ISR is a platform from which multiple research endeavors can be launched, facilitating connections between affected individuals interested in participating in research and researchers actively investigating a variety of aspects of schwannomatosis.
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INTRODUCTION
Schwannomatosis is a syndrome characterized by the presence of multiple schwannomas-nerve sheath tumors composed of Schwann cells. These tumors are nearly always benign but can cause significant morbidity in the form of neuropathic pain, neurologic disability, or regional organ compression [Maccollin et al., 2003; Maccollin et al., 2005] . It is a rare disorder with incidence estimates varying from 1/70,000 to 1/40,000 [Koontz et al., 2013] . Formal diagnostic criteria were established ten years ago [Maccollin et al., 2005; Baser et al., 2006] (Table I) . Individuals with schwannomatosis are known to medical centers around the world, but most centers provide care for only a small number of patients. This reality has contributed to the natural history of schwannomatosis being poorly understood and based on small case series from individual centers [Huang et al., 2004; Gonzalvo et al., 2011 Merker et al., 2012 Li et al., 2016] . Additional complexity comes from the genetic and phenotypic variability of schwannomatosis. Together, these factors impair identification of people affected by schwannomatosis and limits enrollment for clinical and translational studies.
In order to facilitate advances in clinical, translational, and basic science discoveries that could serve people living with schwannomatosis, affected individuals who wish to participate in research must be identified and connected with teams performing research. This daunting task can be simplified by creating an international patient registry that contains well-curated clinical data.
The primary goals of this Children's Tumor Foundation (CTF) registry are: (i) worldwide participation of all interested medical centers and potential research subjects; (ii) reasonable cost; (iii) quality control of the data entered; and (iv) identification of sustainable funding for the registry.
METHODS Design
Stakeholders. The Johns Hopkins Comprehensive Neurofibromatosis Center (JHCNC) was contracted to develop and operate the registry using a web-based model. The first phase of the project involved identifying and aligning experts in the field of schwannomatosis to build consensus about the core, critical data points to collect within the registry. Fifteen investigators from eleven institutions in eight countries participated in the initial planning meeting to decide on the structure and content of the registry. The group concluded that the strengths of an online registry were:
(1) Ease of access at participating sites around the world; (2) Ease with which affected individuals appropriate for particular research studies could be identified; (3) Ability to amass a larger volume of individuals with schwannomatosis than currently existed at any one center.
Concerns regarding a registry model were also discussed and included:
(1) Entry of inaccurate data thereby rendering the registry useless (2) Time required to enter patient data at each site (3) Who "owns" the data entered into the registry As the structure of the registry was designed, all of these concerns were considered and addressed so as to minimize their potential negative impact on the project.
Infrastructure. The infrastructure for the International Schwannomatosis Registry (ISR) was designed with both an operations unit and a governing unit. JHCNFC was identified to take the lead in coordinating the operation of the project. At this site, the principal investigator (PI) and project coordinator developed the functional aspects of the registry, including initial Internal Review Board (IRB)/Ethics Committee approval. Guidance and written materials were provided to all sites wishing to participate in order to facilitate obtaining local IRB/Ethics Committee approvals and consistent enrollment of subjects and data entry. A Steering Committee was established to provide scientific oversight for the ISR. The Steering Committee consists of three voting members who were elected by the members of the initial group of experts. Non-voting members of the Steering Committee are the PI, project coordinator, a representative from the schwannomatosis lay community, and a representative from the funding agency. By-laws for the Steering Committee were proposed by the PI/project coordinator and then edited and ultimately ratified by the initial group of experts.
Registry Structure and Content
The structure and content of the registry were designed to contain limited, de-identified information that provides a general overview of the clinical features of individuals enrolled. This design addresses the anticipated issues of transferring patient data out of an institution into a registry through internet web-based mechanism, as well as the varied IRB/Ethics Committee regulations that were expected due to the international nature of the project.
Additionally, at the initial gathering of experts, key questions of interest in the field of schwannomatosis were identified (Table II) . It was agreed that $20 data points would be designed and collected for each subject that enrolled (Table III ). Querying the registry would then identify subjects suitable for the various research projects prompting the investigator to collaborate with investigators at each site who entered the subjects into the registry. There are sufficient data to allow collaboration across centers yet maintain the independence of individual centers and investigators.
Registry platform and management. ISR data are collected and managed using REDCap, a secure, web-based application designed to support data capture for clinical research studies [Harris et al., 2009] . We also established a website to provide more information about the ISR and assist with the accrual of interested subjects (www.schwannomatosis.com).
Enrollment. Each site identifies their own potential subjects, obtains informed consent and enters their subjects' data into the ISR. Additionally, a mechanism called "long distance enrollment" allows for the inclusion of subjects with schwannomatosis who are not associated with any of the participating sites but who would like to be enrolled into the ISR. Informed consent is obtained via telephone, and potential subjects submit their medical records, including MRI scans and genetic testing reports, to the coordinating site to verify eligibility. Each file is reviewed by a clinician expert in schwannomatosis at the coordinating site to determine whether diagnostic criteria for schwannomatosis are met. If criteria are met, the patient is enrolled in the registry. Data availability and use. The ISR serves as a platform by which people living with schwannomatosis and interested in participating in research can be connected with researchers in this field. Interested researchers submit a letter of intent (LOI) that includes: (i) a summary of the research project; (ii) a description of the eligibility criteria; (iii) specific aims; (iv) a brief description of research design; (v) the significance of the proposed project; and a biographical sketch of study principal investigator. The Steering Committee reviews the study to ensure that it is feasible and that the data sought are appropriate. If the LOI is approved, the ISR operations unit queries the registry and provides the investigator with the contact information for all participating institutions that have entered subjects who meet the eligibility requirements. The investigator then reaches out to the PI at each individual site and they establish a collaboration directly. If a site chooses to participate, the site PI completes all appropriate regulatory materials at their site and contacts eligible subjects to offer participation in the study.
RESULTS
Ten sites from the United States, the United Kingdom, Germany, Italy, Canada, and Israel have enrolled a total of 385 subjects in the ISR. An additional four subjects have been enrolled through the long distance method, with 23 more pending medical records review. The median age at diagnosis is 30 years (range: 5-75), with 50% of patients diagnosed in the third or fourth decades of life (Table IV) . There are similar numbers of males and females enrolled in the ISR. Pain is a major symptom of schwannomatosis, with 75% of the subjects having experienced pain. Seventy two percent of patients presented for medical attention due to pain (either pain alone or along with a palpable mass, and/or neurological deficit). Of those who did not present with pain, 17% presented with a mass 
DISCUSSION
This project has increased communication and collaboration within the schwannomatosis community and has facilitated connections among researchers studying schwannomatosis and affected individuals wanting to participate in research. The successful initiation of three collaborative research projects demonstrates the value of the ISR as a platform to accelerate research in the field of schwannomatosis. These multi-site studies would not have been possible without ISR, as they require more patients than are seen at a single center. Evaluation of study design and relevance to the schwannomatosis community is effected through the process of Steering Committee review of LOIs. This model provides access to the key resource of subject data (clinical data, blood, tissue, imaging) that will allow many of the key questions regarding this disease (SMARCB1, LTZR1 gene effects, the influence of epigenetics, epidemiology, family history, and disease penetration, cause of pain, pain prevention, malignancy risk, etc.) to be addressed by collaborators throughout the world. This model ensures that there is worldwide, immediate access to basic data from almost 400 patients with schwannomatosis, but that no patient data are released without specific consent and the fulfillment of regional regulatory standards. Additionally, each investigator maintains autonomy and can choose which research studies to participate in.
The diagnostic criteria for schwannomatosis are evolving as researchers discover more about this disease (see Table I ). The diagnostic criteria were first established in 2005 and revised in 2006 [Maccollin et al., 2005; Baser et al., 2006] . In 2011 a group of experts in schwannomatosis revisited and updated the diagnostic criteria to include germline mutations in the SMARCB1 gene [Plotkin et al., 2013] . In 2013, the ISR collaborators met to refine the diagnostic criteria of schwannomatosis for inclusion into the registry. Mutations in LZTR1 were added to the molecular diagnosis, and it was agreed that patients with unilateral vestibular schwannoma could be included if the patient was over 40 years of age. The participating sites will be periodically asked to review the latest criteria and perform a quality control check on their patients.
In conclusion, the International Schwannomatosis Registry serves as a core resource of quality controlled information for supporting high-quality, high-impact, multi-site research in schwannomatosis. 
